VOLUME 22 | NUMBER 2 | FEBRUARY 2016 nature medicine l e t t e r S Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials 1 . One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently approved by the FDA to treat ovarian cancer with mutations in BRCA genes. BRCA1 and BRCA2 have essential roles in repairing DNA double-strand breaks, and a deficiency of BRCA proteins sensitizes cancer cells to PARP inhibition 2,3 . Here we show that the receptor tyrosine kinase c-Met associates with and phosphorylates PARP1 at Tyr907 (PARP1 pTyr907 or pY907). PARP1 pY907 increases PARP1 enzymatic activity and reduces binding to a PARP inhibitor, thereby rendering cancer cells resistant to PARP inhibition. The combination of c-Met and PARP1 inhibitors synergized to suppress the growth of breast cancer cells in vitro and xenograft tumor models, and we observed similar synergistic effects in a lung cancer xenograft tumor model. These results suggest that the abundance of PARP1 pY907 may predict tumor resistance to PARP inhibitors, and that treatment with a combination of c-Met and PARP inhibitors may benefit patients whose tumors show high c-Met expression and who do not respond to PARP inhibition alone.
l e t t e r S Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials 1 . One PARP inhibitor, olaparib (Lynparza, AstraZeneca), was recently approved by the FDA to treat ovarian cancer with mutations in BRCA genes. BRCA1 and BRCA2 have essential roles in repairing DNA double-strand breaks, and a deficiency of BRCA proteins sensitizes cancer cells to PARP inhibition 2, 3 . Here we show that the receptor tyrosine kinase c-Met associates with and phosphorylates PARP1 at Tyr907 (PARP1 pTyr907 or pY907). PARP1 pY907 increases PARP1 enzymatic activity and reduces binding to a PARP inhibitor, thereby rendering cancer cells resistant to PARP inhibition. The combination of c-Met and PARP1 inhibitors synergized to suppress the growth of breast cancer cells in vitro and xenograft tumor models, and we observed similar synergistic effects in a lung cancer xenograft tumor model. These results suggest that the abundance of PARP1 pY907 may predict tumor resistance to PARP inhibitors, and that treatment with a combination of c-Met and PARP inhibitors may benefit patients whose tumors show high c-Met expression and who do not respond to PARP inhibition alone.
Increased levels of reactive oxygen species (ROS) in cells can cause oxidative DNA damage that leads to genomic instability and tumor development [4] [5] [6] [7] . ROS-induced DNA damage, such as single-strand breaks (SSBs), recruits PARP1 to lesion sites to orchestrate the DNArepair process through poly-ADP-ribosylation (PARylation) of PARP1 and its target proteins, including histone proteins. PARylated histones destabilize the chromatin structure, allowing the DNA-repair machinery to access the damaged DNA site 8 . Therefore, in theory, inhibiting PARP1 activity would prevent DNA repair and promote death of tumor cells. The tumor suppressors BRCA1 and BRCA2 have essential roles in repairing DNA damage. Notably, mutations in the BRCA1 and BRCA2 genes have been associated with increased risk of ovarian and breast cancers 9 . In addition, tumor cells that lack functional BRCA1 or BRCA2 have demonstrated sensitivity to PARP1 inhibition in both pre-clinical and clinical studies 2, 3, 10 . PARP inhibitors were therefore initially investigated in clinical trials for both ovarian cancer and in triple-negative breast cancer (TNBC)-which can harbor defective BRCA1 or BRCA2 (ref. 11)-as well as in other cancer types 1 . Recently, olaparib was approved by the FDA to treat BRCA1 or BRCA2 mutation-carrying ovarian cancer 12 . Although TNBC is an aggressive subtype of breast cancer that is closely related to basal-like breast cancer (BLBC) 13 , which initially responds to chemotherapy, a majority of TNBCs eventually develop resistance to chemotherapy. There are no approved targeted therapies to treat TNBC 14 . Whereas encouraging results were reported in one study of olaparib treatment of TNBC patients carrying tumors with BRCA1 or BRCA2 mutations 10 , beneficial effects of olaparib treatment were not observed in another cohort 15 . These discrepant clinical observations raise the important question of how to increase the response rate of TNBC-and that of other cancer types-to PARP inhibitors. To address this question, we investigated the molecular mechanisms that contribute to PARP inhibitor resistance in TNBC.
We first noticed that TNBC showed higher oxidative damage DNA than non-TNBC tissue, as indicated by immunohistochemical (IHC) staining for the DNA damage marker 8-hydroxydeoxyguanosine (8-OHdG) on a human breast cancer tissue microarray ( Fig. 1a and Supplementary Table 1 ) and in human breast cancer cell lines (Fig. 1b,c and Supplementary Fig. 1a ) by immunofluorescence staining (1.9-fold difference TNBC versus non-TNBC, 95% confidence interval (CI) = 1.6-2.2) and ELISA assay (2.1-fold difference TNBC versus non-TNBC, 95% CI = 1.8-2.4). Oxidative DNA damage caused by ROS stimulates the activity of PARP1 (refs. 16-20) . In accordance with Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors this, the abundance of ROS ( Fig. 1d and Supplementary Fig. 1b,c) , as measured by the marker 2′,7′-dichlorofluorescein (DCF; intensity: 2.6-fold difference TNBC versus non-TNBC, 95% CI = 1.9-3.3; absorbance 1.33-fold difference, 95% CI = 1.3-1.4), and the level of PARP1 activity (Fig. 1e, right) , as measured by poly(ADP)-ribose (PAR; 2.7-fold difference TNBC versus non-TNBC, 95% CI = 2.3-3.2), were higher in most TNBC cell lines than in non-TNBC cell lines, suggesting a positive association between ROS and PARP1 activity in TNBC.
ROS are also known to activate receptor tyrosine kinases (RTKs) 21 , which are druggable targets commonly overexpressed in TNBC [22] [23] [24] .
To investigate the underlying molecular mechanisms regulating PARP1 response under ROS-induced oxidative stress and to identify potential targets, we searched for RTKs that associate with PARP1 upon ROS stimulation. To this end, PARP1-knockdown MDA-MB-231 TNBC cells re-expressing hemagglutinin (HA)-tagged PARP1 were treated with sodium arsenite to induce ROS production, and a human phospho-RTK antibody array analysis was performed on the wholecell lysates to determine the specific activated PARP1-interacting RTKs by using an HA-specific antibody. The top three candidatesdefined according to the ratio of the density of binding after sodium arsenite treatment to that of untreated cells-were ERBB3, HGFR, and FLT3 (Supplementary Table 2 ). Analysis of The Cancer Genome Atlas (TCGA)'s invasive breast carcinoma cohort ( Supplementary  Fig. 2a ) indicated that only HGFR (encoding c-Met) expression was significantly higher (P = 1e-10) in TNBC than in non-TNBC tumors (Supplementary Fig. 2b) .
c-Met is a proto-oncogene, and c-Met expression correlates with poor survival of patients with TNBC [23] [24] [25] . We detected higher expression of c-Met in TNBC cell lines than in non-TNBC cell lines ( Supplementary Fig. 2c ). We next validated that c-Met and PARP1 co-immunoprecipitate in HEK293T cells ( Supplementary Fig. 3a,b ) and in MDA-MB-231 cells ( Fig. 1f and Supplementary Fig. 3c ). The interaction between c-Met and PARP1 was also detected in other human breast cancer cell lines, such as HCC1937 (endogenous, Supplementary Fig. 3d ), and MDA-MB-436 and MCF-7 (with ectopic expression of c-Met, Supplementary Fig. 3e ,f) in conditions of oxidative stress induced by H 2 O 2 treatment. Because c-Met has been detected in the nucleus 26, 27 and PARP1 is a nuclear protein, we asked whether the c-Met-PARP1 interaction also occurs in the nucleus. Cellular fractionation analysis indicated that about 20-30% and 10-20% of total c-Met translocated into the nucleus upon H 2 O 2 and sodium arsenite treatment, respectively ( Supplementary Fig. 3g,h npg l e t t e r S interaction between c-Met and PARP1 in both the cytosol and nucleus as shown by a Duolink assay ( Fig. 1g) . As shown by treatment of MDA-MB-231 cells with the c-Met inhibitor crizotinib, the kinase activity of c-Met was required for the interaction between c-Met and PARP1, which was enhanced by H 2 O 2 treatment ( Fig. 1h) . Nuclear trafficking of RTKs, including EGFR, from the cell surface has been proposed to use a vesicle membrane-associated pathway 28-30 that requires the motor protein dynein and the SNARE (soluble NSF attachment protein receptor) protein syntaxin 6 (ref. 31) . Nuclear translocation of c-Met in response to H 2 O 2 stimulation also required dynein and syntaxin 6 ( Supplementary Fig. 3i,j) , suggesting that c-Met might use a similar trafficking route. Together, these findings indicated that oxidative stress induces nuclear transport of c-Met and its interaction with PARP1.
To determine whether c-Met influences tumor response to PARP inhibition, we examined TNBC cell line growth and colony formation in the presence of three different PARP inhibitors: the US Food and Drug Administration (FDA)-approved olaparib (AZD2281), as well as veliparib (ABT-888) and rucaparib (AG014699), which are under evaluation in clinical trials 32 . shRNA-mediated knockdown of c-Met expression (by targeting MET) rendered MDA-MB-231 cells more sensitive to all three PARP inhibitors, as indicated by decreased cell viability ( Fig. 2a and Supplementary Fig. 4a-c) . For example, c-Met knockdown cells showed 4.2-fold (shMet-A; 95% CI = 4.0-4.5) or 4.6-fold (shMet-B; 95% CI = 4.4-4.8) growth inhibition when treated with 60 µM ABT-888. Treatment with the c-Met inhibitors crizotinib or foretinib also enhanced MDA-MB-231 sensitivity to the PARP inhibitors ( Fig. 2b and Supplementary Fig. 4d,e) ; anchorage-independent cell growth also decreased when c-Met was knocked down (Supplementary Fig. 4f-h) . Consistent with previous findings 33 , inhibition of c-Met either by shRNAs or small molecules reduced ROS abundance compared to scrambled shRNA or no-treatment control ( Supplementary Fig. 4i,j) , suggesting that a feed-forward mechanism regulating c-Met activation and ROS may be involved in the response to PARP1-mediated DNA damage and PARP inhibition.
To further investigate the function of c-Met during responses to PARP inhibitors, we re-expressed wild-type (WT) and kinase-dead (KD) mutant c-Met in MDA-MB-231 cells subjected to c-Met shRNA-mediated knockdown (Fig. 2c, right) ; re-expression of WT but not KD c-Met increased the cell survival ( Fig. 2c, left and Supplementary Fig. 4k) . Similarly, MCF-7 cells ectopically expressing c-Met had increased cell viability ( Fig. 2d and Supplementary Fig. 5a-c) , clonogenicity ( Fig. 2e and Supplementary Fig. 5d ), and anchorage-independent cell growth ( Supplementary Fig. 5e ,f) in the presence of PARP inhibitors. Of note, the doses used here for the in vitro assays were comparable to those used in previous studies 14, 34 . Together, these results indicated that c-Met activity attenuates response to PARP inhibitors.
Although BRCA1 and/or BRCA2 (BRCA1/2) mutations in and loss of BRCA1/2 are thought to be predictive markers for response npg to PARP inhibitors in ovarian and breast cancers 2,3 , on the basis of the reported objective response, a certain percentage of patients carrying BRCA1/2 mutations do not respond to PARP inhibition 10, 15 .
In agreement with these clinical findings, although both the MDA-MB-436 and HCC1937 breast cancer cell lines harbor BRCA1 mutations, MDA-MB-436 cells are sensitive to and HCC1937 cells are resistant to PARP inhibition 14 . We speculated that the differences in PARP-inhibitor response observed in BRCA1-mutated TNBC cells may be attributed to different expression of c-Met. Indeed, western blot analysis indicated that HCC1937 cells, which expressed higher levels of c-Met than MDA-MB-436 cells (Fig. 2f, top) , were also more resistant to PARP inhibition (Fig. 2f, bottom) ; in addition, knocking down c-Met rendered HCC1937 cells more sensitive to PARP inhibition ( Fig. 2g and Supplementary Fig. 6a,b) . For example, when treated with 38 µM ABT-888, c-Met knockdown cells showed twofold (shMet-A; 95% CI = 1.5-2.5) or 1.9-fold (shMet-B; 95% CI = 1.3-2.5) growth inhibition. In contrast, increasing the ectopic expression of WT but not KD mutant c-Met in MDA-MB-436 cells attenuated the effects of PARP inhibition on cell viability ( Fig. 2h and Supplementary Fig. 6c,d) . Knockdown or ectopic expression of c-Met had no effect on the abundance of BRCA1 and BRCA2 proteins ( Supplementary Fig. 6e,f) .
To further investigate the relationship between BRCA1, BRCA2 and c-Met, we knocked down BRCA1 and BRCA2 expression in a pair of WT-BRCA1 and WT-BRCA2 cell lines with high c-Met (MDA-MB-231) and low c-Met (MDA-MB-157) expression ( Fig. 2i ) and treated them with PARP inhibitors. Knocking down BRCA1 or BRCA2 sensitized only MDA-MB-157 cells expressing low levels of c-Met ( Fig. 2j and Supplementary Fig. 6g-l) . Collectively, these results suggest that enhanced expression of c-Met renders cells resistant to PARP inhibitors in the context of BRCA1 or BRCA2 inactivation, thereby providing a potential molecular explanation for discrepant clinical results involving PARP inhibitor response.
To address whether c-Met activates PARP1, we exposed MDA-MB-231 cells expressing control shRNA or c-Met-specific shRNA to H 2 O 2 , and then subjected them to a comet assay to evaluate the extent of DNA damage. c-Met-knockdown cells had higher tail intensity, which is indicative of increased oxidative DNA damage, than control cells (Supplementary Fig. 7a ). Knockdown of c-Met also reduced DNA repair activity, as measured by oxidative DNA damage ( Supplementary  Fig. 7b) . Consistent with the shRNA results, inhibition of c-Met by foretinib increased the sensitivity of cells to PARP inhibitor-induced DNA damage, as indicated by enhanced γ-H2AX foci formation, an indicator of DNA damage (Fig. 3a) . DNA repair also required the kinase activity of c-Met, as expression of WT but not KD c-Met in MCF-7 cells reduced H 2 O 2 -induced DNA damage; this was restored by pre-treatment with a c-Met inhibitor (Supplementary Fig. 7c-e ). Ectopic expression of c-Met in MCF-7 cells decreased ABT-888-induced γ-H2AX foci formation, as compared to the vector control (Supplementary Fig. 7f) . MDA-MB-231 cells expressing c-Met-specific shRNA had higher γ-H2AX foci formation than those with vector control after ABT-888 treatment (Fig. 3b, top, left) ; re-expression of WT c-Met but not re-expression of vector control (Fig. 3b, bottom, left) , KD c-Met, or WT c-Met plus pre-treatment with the c-Met inhibitor crizotinib restored this (Fig. 3b, top, right) . These findings together suggest that c-Met kinase activity enhances the DNA-repair function of PARP1.
Given that c-Met and PARP1 physically associate in vivo (Fig. 1f,g  and Supplementary Fig. 3a-f) , we speculated that c-Met could phosphorylate PARP1 under oxidative stress. Indeed, in HEK293T cells expressing FLAG-tagged c-Met and V5-tagged PARP1, H 2 O 2 induced PARP1 tyrosine phosphorylation (Fig. 3c) . The software program NetworKIN (V2.0) 35 predicted that Tyr907 (Y907), which is located on the H-Y-E motif in the catalytic domain of PARP1 (ref. 36) , is the c-Met phosphorylation site. An in vitro kinase assay showed that compared to WT PARP1, phosphorylation, as read out by γ-32 P incorporation, was substantially reduced in the Y907F mutant, but not in PARP1 bearing a mutation at Y986, another Tyr residue in the H-Y-E domain (Supplementary Fig. 8a,b) . These results suggest that Y907 is a bona fide c-Met phosphorylation site.
Because Y907 is located within the catalytic domain of PARP1, we next asked whether Y907 phosphorylation affects the function of PARP1. We stably expressed WT, Y907F (non-phosphorylatable) or Y907E (phosphomimetic)-mutant PARP1 in PARP1-knockdown MDA-MB-231 cells (Fig. 3d, left) and measured H 2 O 2 -induced DNA damage by comet assay. PARP1-knockdown cells had more DNA damage than control cells (Fig. 3d, center and right) . Re-expression of WT PARP1 reduced DNA damage compared to the Y907F mutant, and cells expressing the Y907E mutant had the least amount of DNA damage (Fig. 3d, right) . To determine whether phosphorylation of PARP1 at Y907 affects its activity, we compared the PARylation (PAR) levels in MDA-MB-231 cells expressing WT and mutant PARP1. Cells expressing WT PARP1 had increased PAR in response to H 2 O 2 (Fig. 3e) . Cells expressing the phosphomimetic Y907E mutant had higher levels of PAR than the non-phosphorylatable Y907F mutants; however, both mutants were no longer sensitive to H 2 O 2 treatment (Fig. 3e) . To further investigate the functional importance of PARP1 phosphorylation at Y907, we generated an antibody to specifically detect pY907 (Supplementary Fig. 8c-g) . Treatment with either crizotinib or foretinib abolished H 2 O 2 -induced phosphorylation of PARP1 at Y907 (Fig. 3f) . These results suggest that H 2 O 2 -induced WT PARP1 activity requires Y907 phosphorylation.
We then asked whether c-Met-mediated phosphorylation of Y907 of PARP1 affects PARP inhibitor response. MDA-MB-231 cells expressing WT or mutant PARP1 were treated with or without H 2 O 2 and/or increasing concentrations of ABT-888, and they were then subjected to a PARP enzyme activity assay to measure the median inhibitory concentration (IC 50 ) of ABT-888. The activity of the phosphomimetic Y907E mutant was similar to that of WT PARP1 treated with H 2 O 2 (higher IC 50 ), whereas the activity of the non-phosphorylatable Y907F mutant was similar to that of WT PARP1 without H 2 O 2 (lower IC 50 ) (Supplementary Fig. 8h ). In addition, we measured the direct binding of WT and mutant (Y907F and Y907E) PARP1 to ABT-888 by an in vitro isothermal titration calorimetry (ITC) assay (Supplementary Fig. 8i) . The results indicated a higher K d value for the PARP1 Y907E mutant than either the WT or the Y907F mutant, suggesting that phosphorylated PARP1 exhibited a lower binding affinity for ABT-888 than the non-phosphorylated form. Together, these results indicate that phosphorylation of PARP1 at Y907 attenuates the inhibitory effect of ABT-888.
Next, in MDA-MB-231 cells expressing PARP1-specific shRNA (i.e., targeting PARP1), we re-expressed WT, Y907F-mutant or Y907Emutant PARP1 (Supplementary Fig. 8j ) and subjected them to control or c-Met-specific shRNA knockdown and/or ABT-888 treatment. We then evaluated the extent of DNA damage by γ-H2AX foci formation (Fig. 3g) . Knocking down c-Met sensitized cells to ABT-888-induced DNA damage in cells expressing WT PARP1, but it did not affect DNA repair in cells expressing Y907F-mutant or Y907E-mutant PARP1. We observed similar results in clonogenic cell survival (Fig. 3h) and cell viability assays (Supplementary Fig. 8k,l) , and by using the inhibitor AG014699 instead of ABT-888.
npg l e t t e r S To evaluate the clinical relevance of our findings, we validated the antibody specific to pY907-PARP1 in formalin-fixed paraffinembedded (FFPE) tumor tissues obtained from breast cancer patients ( Supplementary Fig. 9a ). Next, we used this antibody to measure pY907-PARP1 abundance in a human breast cancer tissue microarray by IHC staining; we observed a positive correlation between n.s. npg pY907-PARP1 and c-Met expression in both TNBC ( Fig. 4a and Supplementary Table 3 ) and non-TNBC tumors ( Supplementary  Fig. 9b ). High ROS (8-OHdG) also correlated with high pY907-PARP1 abundance (Supplementary Fig. 9c) . These results suggest that intracellular ROS may induce phosphorylation of PARP1 at Y907 in a c-Met-dependent manner. Next, we examined the effects of combining c-Met inhibitors (foretinib and crizotinib) and PARP inhibitors (ABT-888 and AG014699). Both the ABT-888-foretinib and AG014699-crizotinib combinations demonstrated synergistic cell growth inhibition in MDA-MB-231 and HCC1937 TNBC cells (Fig. 4b) , but not in MCF10A mammary epithelial cells (Supplementary Fig. 10a) . The combined treatment of AG014699 and crizotinib also synergized to suppress clonogenicity (Supplementary Fig. 10b,c) and anchorage-independent growth ( Fig. 4c and Supplementary  Fig. 10d ). We observed similar inhibitory effects on clonogenic cell survival for the ABT-888-foretinib combination ( Supplementary  Fig. 10e) . Synergistic inhibition of c-Met and PARP1 was also observed in another breast cancer cell line, BT549 ( Supplementary  Fig. 10f ). H 2 O 2 -induced phosphorylation of Y907-PARP1 was abolished by c-Met inhibition (Supplementary Fig. 10g ). In addition to human breast cancer cell lines, we evaluated the effect of the combination treatment in two mouse mammary tumor cell lines derived from a transgenic mouse model of TBNC that expressed constitutively active human c-Met 37 . Combined treatment with c-Met and PARP inhibitors synergistically inhibited mouse tumor cell growth ( Supplementary Fig. 10h,i) . Also, pY907-PARP1 was stimulated by H 2 O 2 and abolished by c-Met inhibition in these mouse cell lines (Supplementary Fig. 10j ).
We also evaluated the effect of combining PARP and c-Met inhibitors in vivo in established TNBC xenograft models. In MDA-MB-231 xenograft tumor models, combination treatment (AG014699crizotinib and ABT-888-foretinib) substantially reduced tumor growth compared to either inhibitor alone (Fig. 4d,e and Supplementary Fig. 11a,b) . The AG014699-crizotinib combination also inhibited growth of mouse mammary tumor cells (A1034) in a syngeneic FVB mouse model and in an HCC1937 TNBC xenograft tumor model ( Supplementary Fig. 11c,d) . Increased apoptosis (as measured by TUNEL staining), reduced cell proliferation (as measured by Ki67 staining) and greater DNA damage (as measured by γ-H2AX staining) were observed in MDA-MB-231 xenograft tumor tissues harvested from mice within 24 h after the last treatment ( Fig. 4f, Supplementary Fig. 11e ). In addition, the overall health of the mice was not adversely affected by either the AG014699-crizotinib or ABT-888-foretinib combination, as compared to no treatment or single treatment (as indicated by clinical chemistry analysis and body weight; Supplementary Fig. 11f-l) .
Because PARP inhibitors have been used in clinical trials for multiples cancer types, including lung cancer, we also tested a non-TNBC cell line (MCF-7 with ectopic expression of c-Met) and two lung cancer cell lines (H1993 and A549) in vitro and in vivo. Synergistic inhibition of cell growth was observed in the MCF7 l e t t e r S with ectopic expression of WT c-Met (MCF-7/c-Met) and H1993 cells (high c-Met expression) but not in MCF7 with vector control (MCF7/control), MCF7 with ectopic expression of KD c-Met (MCF7/c-Met KD), or A549 (low c-Met expression) cells ( Fig. 4g and Supplementary Fig. 12a,b) . c-Met inhibitor pre-treatment abolished H 2 O 2 -induced pY907-PARP1 in both MCF-7/c-Met and in H1993 cells (Supplementary Fig. 12c,d) . Furthermore, the combined treatment of AG014699 and crizotinib demonstrated significant anti-tumor activity in MCF/c-Met breast cancer and H1993 lung cancer xenograft tumor models ( Fig. 4h,i) .
Taken together, our study revealed that c-Met-phosphorylated PARP1 at Y907 leads to PARP inhibitor resistance ( Supplementary  Fig. 12e ) and identified c-Met as an important regulator of PAPR inhibitor response, suggesting that pY907-PARP1 may be a useful marker with which to stratify patients for PARP inhibitor treatment alone or in combination with a c-Met inhibitor. Of note, many studies have found aberrant c-Met activation and increased expression of c-Met in TNBC tumors 38 . Notably, we observed positive correlation between c-Met and pY907-PARP expression in TNBC patient samples (Fig. 4a) . On the basis of our findings, about one-third (24/77 in Fig. 4a and Supplementary Table 3 ) of TNBC patients who are positive for pY907-PARP1 and c-Met would probably be resistant to PARP inhibitor alone, and they could benefit from the combined therapy of c-Met and PARP inhibition using pY907-PARP1 and c-Met as biomarkers.
It should be mentioned that the combined inhibition of EGFR and PARP induces synthetic lethality in TNBC 39 . However, the underlying mechanism of this combination is not yet clear, and given that EGFR was also identified from our phospho-RTK antibody array analysis, it is conceivable that EGFR may induce resistance to PARP inhibitors through a similar mechanism in a subpopulation of patients who do not respond to PARP inhibition. It will be important to further investigate the relationship between PARP1 and EGFR and between PARP1 and phosphatases that can dephosphorylate pY907 or other functionally important phosphorylation sites of PARP1. Moreover, investigating whether other protein kinases also regulate PARP inhibitor response may reveal a new perspective on the development of combination therapy strategies and benefit a broader population of patients.
PARP inhibitors are being used in clinical trials for many cancer types in addition to TNBC 1 . c-Met is a proto-oncogene that is overexpressed in multiple cancer types 40 . Although we initiated our study using TNBC samples for historical (original synthetic lethality) and clinical (no effective target therapy for TNBC in the clinic) reasons, we also demonstrated that the combined treatment of c-Met and PARP inhibitors effectively reduced tumor growth in MCF-7/c-Met (Fig. 4h) and c-Met-expressing H1993 NSCLC xenograft tumor models ( Fig. 4i) . These results raise the interesting possibility that cancer patients with tumors that overexpress c-Met may benefit from this combination therapy regardless of the cancer type. Thus, it may be worthwhile to systematically test whether the combined inhibition of both PARP and c-Met also exhibits synergistic therapeutic effects in other types of tumors.
MeTHODS
Methods and any associated references are available in the online version of the paper.
using the IVIS Imaging System to assess tumor growth. Mice were injected with 100 µl of d-luciferin (Xenogen; 15 mg/ml in PBS). After 10 min, mice were anesthetized with a mixture of oxygen and isoflurane (Inhalation Anesthesia System; Matrix Medical, Orchard Park, NY) and imaged using the IVIS Imaging System. Imaging parameters were maintained across experiments for comparative analyses. Tumors were not allowed to grow larger than allowed by the animal welfare protocol.
Tumor samples were collected after final treatment and analyzed by immunofluorescence staining. For toxicity assessment, mice were weighed before and after treatment (on day 21 for AG014699 and crizotinib, and on day 16 for ABT-888 and foretinib. Blood samples were collected from the orbital sinus using a microhematocrit tube after each treatment and subjected to biochemical analysis for liver marker enzymes alanine transaminase (ALT) and aspartate transaminase (AST) and kidney marker by-products creatinine and blood urea nitrogen to evaluate treatment toxicity by COSBA INTERGRA 400 plus (Roche Diagnostics, Rotkreuz, Switzerland) at The Department of Veterinary Medicine and Surgery, The University of Texas MD Anderson Cancer Center. All in vivo experiments were conducted with 10 mice for each treatment and control group. No statistical methods were used to predetermine sample size.
Statistical analyses. Unless otherwise noted, each sample was assayed in triplicate. For in vitro analyses, each experiment was repeated at least three times. All error bars represent s.d. Student's t test was used to compare two groups of independent samples. Repeated-measures ANOVA analysis was used to evaluate the statistical significance of dose curve response. Correlations were analyzed using the Pearson chi-square test. A P value of <0.05 was considered statistically significant. No statistical methods were used to determine sample size.
